EC Number |
Application |
Reference |
---|
2.7.7.19 | biotechnology |
assay in microtiter format |
642987 |
2.7.7.19 | drug development |
polyadenylation inhibition represents one mode of action for 8-chloroadenosine and 8-aminoadenosine in hematological malignancies, among several possible mechanisms. RNA-directed drugs may offer a valuable strategy in targeting indolent cancers, such as multiple myeloma |
662270 |
2.7.7.19 | medicine |
enzyme is overexpressed in cancers |
642982 |
2.7.7.19 | medicine |
PAP activity is used to measure the effects of anticancer drugs etoposide and cordycepin in two epithelial cancer cell lines, HeLa (human epithelioid cervix carcinoma) and MCF-7 (human breast cancer). MCF-7 is found to express significantly more PAP than the cervical cancer cell line, HeLa. Treatment of HeLa cells with etoposide (0.034 mM) leads to a continuous increase in PAP activity levels during the 2 h of exposure. Important differential modulations in both PAP enzyme activity and isoforms are observed, occurring earlier than chromatin condensation and cleavage, in both epithelial cancer cell lines tested. Treatment of HeLa cells with cordycepin (0.067 mM) leads to a continuous increase in PAP activity and isoform levels after 4 h of exposure. In the case of MCF-7 cells, treatment with 0.067 mM cordycepin leads to a decrease in both PAP II enzyme activity and phosphorylated PAP isoforms after 4 h of exposure. Thus high PAP activity levels in breast cancer cells may be an independent unfavorable prognostic factor contributing to the malignant phenotype of cells. The differentiated modulations of PAP in the two epithelial cancer cell lines correlate to changes in the cell cycle, suggesting that in this case PAP II follows the cell cycle despite the course of apoptosis. Thus in these two epithelial cell lines PAP modulations follow cell cycle progression rather than apoptosis |
661293 |
2.7.7.19 | medicine |
the enzyme possesses tumor-suppressing activity and sensitizes breast cancer cells to chemotherapy drugs. In breast cancer patients, high levels of enzyme correlate with an improved prognosis |
760831 |
2.7.7.19 | medicine |
use as prognostic factor for early recurrence and death in breast cancer patients |
642975 |